NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Receives Average Recommendation of “Hold” from Brokerages

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has been given an average rating of “Hold” by the five research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $11.6667.

NMTC has been the subject of several research analyst reports. Weiss Ratings lowered shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. JonesTrading initiated coverage on shares of NeuroOne Medical Technologies in a research note on Monday, March 2nd. They issued a “buy” rating and a $9.00 price objective for the company. LADENBURG THALM/SH SH lifted their price objective on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a research note on Wednesday. Zacks Research lowered shares of NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 13th. Finally, Wall Street Zen upgraded shares of NeuroOne Medical Technologies to a “sell” rating in a research note on Saturday, February 21st.

Insider Activity

In other news, insider David J. Wambeke bought 166,666 shares of NeuroOne Medical Technologies stock in a transaction dated Sunday, March 1st. The stock was purchased at an average price of $4.02 per share, for a total transaction of $669,997.32. Following the purchase, the insider directly owned 166,666 shares in the company, valued at $669,997.32. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have sold 2,438 shares of company stock valued at $11,702. Corporate insiders own 11.80% of the company’s stock.

Institutional Trading of NeuroOne Medical Technologies

Several institutional investors have recently made changes to their positions in NMTC. Goldman Sachs Group Inc. bought a new stake in shares of NeuroOne Medical Technologies in the 1st quarter worth $84,000. XTX Topco Ltd bought a new stake in shares of NeuroOne Medical Technologies in the 2nd quarter worth $51,000. Vanguard Group Inc. grew its stake in shares of NeuroOne Medical Technologies by 31.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock worth $1,403,000 after acquiring an additional 375,639 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of NeuroOne Medical Technologies in the 3rd quarter worth $88,000. Finally, Susquehanna International Group LLP bought a new stake in shares of NeuroOne Medical Technologies in the 3rd quarter worth $47,000. Institutional investors own 16.07% of the company’s stock.

NeuroOne Medical Technologies Stock Down 8.5%

NASDAQ:NMTC opened at $4.21 on Friday. The company has a fifty day moving average of $4.55 and a 200-day moving average of $4.55. The firm has a market capitalization of $36.29 million, a P/E ratio of -4.95 and a beta of 0.60. NeuroOne Medical Technologies has a twelve month low of $3.27 and a twelve month high of $6.96.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The company had revenue of $2.39 million during the quarter, compared to the consensus estimate of $2.58 million. NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 98.33%. On average, analysts anticipate that NeuroOne Medical Technologies will post -0.35 EPS for the current fiscal year.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.